Loading ...
Sorry, an error occurred while loading the content.


Expand Messages
  • claudine intexas
    LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 31, 2003-- Aethlon Medical Inc. (OTCBB:AEMD) today announced that initial pre-clinical human blood studies of the
    Message 1 of 1 , Feb 1, 2003
      LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 31, 2003--
      Aethlon Medical Inc. (OTCBB:AEMD) today announced that initial
      pre-clinical human blood studies of the company's new
      HCV-Hemopurifier(TM) have documented a consistent ability to remove
      58 percent of Hepatitis-C virus (HCV) from infected blood in two

      The data was presented at the "International Conference on Dialysis
      V" which ends today in Miami, Florida. The data compares favorably
      with Aethlon's lead product AEMD-45, which is a HIV treatment
      Hemopurifier(TM) that is able to remove 55 percent of HIV from
      human blood in three hours and in excess of 85 percent in 12 hours.

      "This data helps substantiate the clinical expectation that our
      Hemopurifier(TM) treatment platform can be effective for numerous
      disease states," said James A. Joyce, Chairman and CEO. "Our data
      becomes especially important when considering the magnitude of HIV
      and HCV infections and the reality that both viruses can mutate to
      defeat current drug therapies."

      According to the Centers for Disease Control (CDC), over 200 million
      people worldwide are
      infected with the Hepatitis-C (HCV) virus. In the United States,
      HCV has become the most common chronic, blood-borne disease with
      nearly 4 million infected. Chronic and progressive Hepatitis C,
      which represents 80-90 percent of all cases, has significant
      morbidity and mortality rates, and is the leading cause of liver
      disease and transplantation.

      Richard Tullis, Ph.D., chief scientific officer at Aethlon stated,
      "This is a significant advance in Aethlon's virus treatment
      platform. The possibility now exists that we will be able to
      deliver a medical device that can simultaneously treat both HIV
      and HCV infections, a factor that could be crucial for the large
      population of patients that are infected with both diseases."

      About Aethlon Medical

      Aethlon Medical develops therapeutic devices that treat HIV/AIDS,
      Hepatitis-C (HCV) and other infectious diseases. In pre-clinical
      testing, Aethlon has published that AEMD-45, its lead product for
      treating HIV, is able to remove 55 percent of HIV from infected
      human blood in three hours and in excess of 85 percent in 12 hours.
      Aethlon has also documented that AEMD-45 removes up to 90 percent
      of toxic viral proteins that deplete immune cells during the
      equivalent of a one-hour treatment. The AEMD-45 therapeutic device,
      like all product offerings from Aethlon Medical, is developed from
      an expansive platform technology known as the Hemopurifier(TM),
      which employs a proprietary method to increase the capability of
      FDA cleared artificial kidneys (dialysis cartridges) to remove
      targeted intoxicants from the blood. In the case of AEMD-45,
      dialysis cartridges are modified to mimic the immune system's
      response to clear infectious virus from circulation before healthy
      cells are infected. AEMD-45 is designed to fill the urgent need
      for new treatments that are effective in reducing viral load,
      decrease the likelihood of treatment resistance and treat without
      the toxic side-effects associated with AIDS drugs. For more
      information, visit the company's Web site at www.AethlonMedical.com.

      Certain of the statements herein may be forward-looking and
      involve risks and uncertainties. Such forward-looking statements
      involve assumptions, known and unknown risks, uncertainties and
      other factors which may cause the actual results, performance or
      achievements of Aethlon Medical Inc. to be materially different
      from any future results, performance or achievements expressed or
      implied by the forward-looking statements. Such potential risks
      and uncertainties include, without limitation, the company's
      ability to raise capital when needed, the company's ability to
      complete the development of its planned products, the ability of
      the company to obtain FDA and other regulatory approvals permitting
      the sale of its products, the company's ability to manufacture its
      products and provide its services, the impact of government
      regulations, patent protection on the company's proprietary
      technology, product liability exposure, uncertainty of market
      acceptance, competition, technological change, and other risk
      factors. In such instances, actual results could differ materially
      as a result of a variety of factors, including the risks
      associated with the effect of changing economic conditions and
      other risk factors detailed in the company's Securities and
      Exchange Commission filings.


      Aethlon Medical Inc.

      James A. Joyce, 858/456-5777

      SOURCE: Aethlon Medical Inc.

      Do you Yahoo!?
      Yahoo! Mail Plus - Powerful. Affordable. Sign up now.
    Your message has been successfully submitted and would be delivered to recipients shortly.